What to do when two oral agents fail to control type 2 diabetes - A matter of opinion or a matter of fact?

American Journal of Medicine

Volumn 116, Issue 4, 2004, Pages 276-278

  Ahmann, Andrew J ^a,b   Riddle, Matthew C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CONJUGATED ESTROGEN; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; ISOPHANE INSULIN; MEDROXYPROGESTERONE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 1242283926     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.11.012     Document Type: Editorial

References (19)

1. Biswas P., Wilton L.V., Chakir S.A. Troglitazone and liver function abnormalities lessons from a prescription event monitoring study and spontaneous reporting . Drug Saf. 24:2001;149-154.
2. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group . JAMA. 281:1999;2005-2012.
3. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev. 18:(Suppl 3):2002;S70-76.
4. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes scientific review . JAMA. 287:2002;360-372.
5. Riddle M.C., Hart J.S., Bouma D.J., et al. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care. 12:1989;623-629.
6. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 333:1995;541-549.
7. Dailey G.I., Noor M.A., Park J., et al. Glyburide/metformin tablets in combination with rosiglitazone improve glycemic control in patients with type 2 diabetes A randomized, double-blind trial . Am J Med. 116:2003;223-229.
8. Aljabri H, Kozak S, Thompson D. A comparison of adding pioglitazone or insulin to patients with type 2 diabetes in poor control on maximal doses of sulphonylurea and metformin: a prospective, randomized, 16 week trial. Am J Med. 2003;116:230-235.
9. Schwartz S., Sievers R., Strange P., et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs efficacy, safety, and cost analysis . Diabetes Care. 26:2003;2238-2243.
10. Riddle M.C., Rosenstock J., Gerich J. The Treat-to-Target Trial Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients . Diabetes Care. 26:2003;3080-3086.
11. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 51:2002;2796-2803.
12. Juhl C.B., Hollingdal M., Porksen N., et al. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility . J Clin Endocrinol Metab. 88:2003;3794-3800.
13. Stumvoll M. Thiazolidinediones-some recent developments. Expert Opin Investig Drugs. 12:2003;1179-1187.
14. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus an intravascular ultrasound scanning study . Am Heart J. 146:2003;E5.
15. Davidson M.B. Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care. 26:2003;3184-3186.
16. Alvarsson M., Sundkvist G., Lager I., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 26:2003;2231-2237.
17. Dandona P., Aljada A., Bandyopadhyay A. The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care. 26:2003;516-519.
18. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results From the Women's Health Initiative randomized controlled trial . JAMA. 288:2002;321-333.
19. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA. 288:2002;2981-2997.